Answers are grounded in this paper and cite their sources.
Alzheimer's disease (AD) is increasingly understood as a systemic condition involving central and peripheral nervous and immune systems. This shift has directed attention to the gut, where the enteric nervous system (ENS) and its enteric glial cells sit at the interface of the gut-brain axis. Gastrointestinal disturbances, altered microbiota, and enteric deposits of amyloid-β and tau are all documented in AD, prompting closer investigation of the role enteric glia and the ENS play in disease progression. As the gut ages, it becomes a primed environment in which inflammation, dysbiosis, and protein deposition reinforce one another, raising an inflammatory tone that the gut-brain axis delivers to the brain. Enteric glial cells play a double-edged role in this process: in homeostatic states, they provide trophic and protective support, but in reactive states they amplify inflammatory signaling, weaken the epithelial barrier, and disturb neuronal circuits. On current evidence, the gut is best understood as an amplifier of AD pathology rather than its initiator, and enteric glia as double-edged modulators rather than primary drivers. Because this evidence remains convergent and partially indirect, this review outlines the priorities needed to test the proposed framework, identifying enteric glial reactivity as a target for future mechanistic and therapeutic investigation.
No takes yet. Share an insight, caveat, or question.
Koflanovich et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: